Details of the Drug
General Information of Drug (ID: DMPKBVR)
| Drug Name |
2-acetamido-5-sulfonamidoindane
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
CHEMBL184674; N-(5-Sulfamoyl-indan-2-yl)-acetamide; 2-acetamido-5-sulfonamidoindane; Indanesulfonamide Derivative 6; SCHEMBL1971499; N-(5-sulfamoyl-2,3-dihydro-1H-inden-2-yl)acetamide; BDBM11029; CTK6A0685; RVPDXKXWYPPTAL-UHFFFAOYSA-N; N-acetyl-5-sulfamyl-2-indanamine; Acetamide, N-[5-(aminosulfonyl)-2,3-dihydro-1H-inden-2-yl]-; AKOS015966079; 74124-93-9
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 254.31 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 0.2 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||||||||


